Atrial fibrillation is one of the most common cardiac arrhythmias and is closely associated with stroke.Restoring sinus rhythm is particularly important for the management of atrial fibrillation,with clinical methods commonly including pharmacological cardioversion,electrical cardioversion,and radiofrequency ablation,or a combination of these approaches.Amiodarone is the most frequently used antiarrhythmic drug,but it can cause a variety of extracardiac side effects,limiting its clinical application.Nifekalant is a pure potassium ion channel blocker,primarily used for ventricular arrhythmias.Recent studies have suggested that nifekalant also has good efficacy for atrial fibrillation,although it is less commonly used.Therefore,the aim here is to summarize existing clinical experience to better guide the application of nifekalant in the treatment of atrial fibrillation.
NETL
NSTL
万方数据
